CSL announces new $235m biotech facility

CSL announced today that it will invest $235 million over the next five years to develop a large scale biotechnology facility at its manufacturing site in Broadmeadows focussed on the late-stage development of new therapies for cancer, bleeding disorders, inflammation and infection.

The comany said that it would be the first project of its kind ever undertaken in Victoria.

Currently the site plays host to advanced manufacturing facilities producing a range of highly specialised medicines with these operations to be fully integrated with the new facility.

Commenting on today’s announcement, CSL’s CEO, Dr Brian McNamee said that the new facility would enable CSL to build on its extensive R&D portfolio to develop innovative new products for clinical trials and future patient use and would create around 330 highly skilled research positions.

“This significant project enables us to build on our existing capabilities and research collaborations, further develop the nation’s biotechnology skills and work towards our important goal of improving the lives of people with life-threatening disease,” he said.